SNF5, a core component of the SWI/SNF chromatin remodeling complex, is expressed as two isoforms, SNF5a and SNF5b. SNF5 is a tumor suppressor, as mutation of SNF5 leads to tumor formation and cooperates with p53 deficiency to enhance cancer susceptibility. Interestingly, lack of SNF5 inhibits cell survival and embryonic development, potentially through abnormal activation of p53. To further examine this, we generated cell lines in which SNF5a, SNF5b or both can be inducibly knocked down. We found that SNF5 knockdown leads to cell-cycle arrest in G 1 , and SNF5a and SNF5b are functionally redundant. We also showed that SNF5 knockdown impairs p53-dependent transcription of p21 and murine double minute 2. However, contrary to earlier reports that p53 is activated by SNF5 knockout in murine cells, SNF5 knockdown leads to decreased, but not increased, expression of both basal and stress-induced p53 in multiple human cell lines. In addition, we showed that SNF5 knockdown induces adenosine monophosphate-activated protein kinase activation and inhibits eIF4E expression. Finally, we showed that SNF5 knockdown inhibits p53 translation by eIF4E and replacement of eIF4E in SNF5 knockdown cells restores p53 expression and cell survival. Together, our study results suggest that the p53 pathway is regulated by, and mediates the activity of, SNF5 in tumor suppression and prosurvival.
Introduction
The SWI/SNF complex is an evolutionarily conserved multisubunit chromatin remodeling complex that uses ATP to mobilize nucleosomes and remodel chromatin (Kingston and Narlikar, 1999) . As a core subunit, human SNF5 is required for both the in vivo and the in vitro remodeling activities of SWI/SNF (Carlson and Laurent, 1994; Peterson, 1996) . The SNF5 gene is expressed as two alternative spliced forms, SNF5a and SNF5b. SNF5 is found to be mutated or deleted in various tumors including rhabdoid, brain and lung cancers, suggesting that SNF5 functions as a potential tumor suppressor (Versteege et al., 1998; Sevenet et al., 1999a Sevenet et al., , 1999b Roberts and Orkin, 2004) . Indeed, loss of heterozygosity of SNF5 predisposes mice to cancer development at a high frequency (Klochendler-Yeivin et al., 2000; Roberts et al., 2000; Guidi et al., 2001 ). In addition, conditional inactivation of SNF5 in hematopoietic tissues resulted in an extremely rapid onset of CD8 þ lymphomas (Roberts et al., 2002) , potentially through transcriptional activation of p16 and inhibition of cyclin D1 (Zhang et al., 2002; Oruetxebarria et al., 2004; Vries et al., 2005; Chai et al., 2007) . Interestingly, SNF5 is also required for cell survival and differentiation (Gresh et al., 2005; Caramel et al., 2008) . Homozygous deletion of SNF5 in mice causes embryonic lethality, and conditional inactivation of SNF5 in mice leads to rapid bone marrow failure and death (Klochendler-Yeivin et al., 2000; Roberts et al., 2000 Roberts et al., , 2002 . In addition, targeted inactivation of SNF5 in liver impairs glucose metabolism and cell differentiation (Gresh et al., 2005) .
P53 is a transcription factor and regulates target genes involved in cell death and survival in response to stresses (Ko and Prives, 1996; Harms et al., 2004) . One study showed that SNF5 is capable of regulating p53 transcriptional activity in vitro (Lee et al., 2002) . Recently, we showed that Brg1-and Brm-containing SWI/SNF complexes differentially regulate p53 transcriptional activity (Xu et al., 2007) . In addition, loss of p53 accelerates tumor formation in mice bearing conditional inactivation of SNF5, suggesting that SNF5 and p53 function together to prevent cancer development (Isakoff et al., 2005; Klochendler-Yeivin et al., 2006) . However, whether endogenous SNF5 has an effect on p53-dependent transcription and whether p53 target genes have a role in SNF5 prosurvival function remain to be determined. In this study, we showed that knockdown of SNF5 in tumor cells leads to cell-cycle arrest in G 1 . We also showed that p53 translation is inhibited on SNF5 knockdown, and replacement of eIF4E in SNF5 knockdown cells restores p53 expression and cell survival. Thus, we hypothesized that the p53 pathway is regulated by, and mediates the activity of, SNF5 in tumor suppression and prosurvival.
Results
Generation of cell lines in which total SNF5 or an individual SNF5 isoform can be inducibly knocked down SNF5a, a polypeptide with 385 amino acids, and SNF5b, a polypeptide with 376 amino acids, are identical, except that SNF5b lacks nine amino acids between codons 69 and 77 (Figure 1a ). To investigate a potential role of SNF5 in the p53 pathway, we generated MCF7 and RKO cell lines, which inducibly express small interfering RNAs (siRNAs) targeting both SNF5 isoforms under the control of the tetracycline-regulated promoter. To reduce the nonspecific effect of RNA interference, we used two siRNAs, siSNF5-1049 and siSNF5-1063, to knock down total SNF5. siSNF5-1049 was used to generate SNF5-KD in both MCF7 and RKO cells. Two representative SNF5-KD MCF7 and RKO cell lines, MCF7-SNF5-KD#5/#73 and RKO-SNF5-KD#10/#11, are shown in Figures 1b and c. siSNF5-1063 was used to generate SNF5-KD MCF7 cell lines. Two representative cell lines, MCF7-SNF5-KD#18/#24, are shown in Figure 1b . Western blot analysis showed that both isoforms of SNF5 were expressed in MCF7 and RKO cells, and the levels of SNF5 proteins were significantly decreased on expression of either siSNF5-1049 or siSNF5-1063 (Figures 1b  and c) . We mention that in MCF7-SNF5-KD#5 cells, both SNF5a and SNF5b were expressed but overlapped due to insufficient separation. We also mention that the relative basal level of SNF5a is lower in MCF7 cells than in RKO cells (Figures 1b and c) . Next, to investigate the physiological relevance of each isoform, we generated multiple MCF7 and RKO cell lines that inducibly express siRNAs targeting each individual SNF5 isoform. Western blot analysis showed that the levels of SNF5a and SNF5b in MCF7 and RKO cells were significantly decreased on expression of siRNA targeting SNF5a and SNF5b, respectively (Figure 1d ). Interestingly, we found that knockdown of one isoform led to an increased expression of other isoform, especially in MCF7 cell lines in which SNF5b was knocked down (Figure 1d , compare lanes 5 and 7 with 6 and 8, respectively). This suggests that SNF5a and SNF5b are compensatory in their expression. Previously, expression of SNF5 alleles was found to be compensatory. On knockout of one allele, expression of the remaining allele was found to be increased to compensate for the lost expression from the deleted allele (Guidi et al., 2004) . Here, for the first time, we showed that a compensatory effect exists between SNF5 isoforms, possibly to maintain a proper level of SNF5 proteins, suggesting that SNF5 is necessary for cell survival. Knockdown of total SNF5, but not an individual SNF5 isoform, inhibits cell proliferation To determine whether endogenous SNF5, especially an individual SNF5 isoform, has a long-term impact on cell survival, we performed colony formation assay and showed that on knockdown of total SNF5, colony formation by MCF7 and RKO cells was significantly inhibited (Figure 2a) , consistent with previous report that SNF5 is necessary for embryonic development (Klochendler-Yeivin et al., 2000; Roberts et al., 2000 Roberts et al., , 2002 . Interestingly, knockdown of either SNF5a or SNF5b had no significant effect on colony formation in MCF7 cells (Figure 2b) . As a control, tetracycline had no effect on cell proliferation in parental MCF7 or RKO cell lines (data not shown). We also performed cell proliferation assay and showed that cell growth was suppressed by knockdown of total SNF5 over a 5-or 7-day testing period in MCF7 and RKO cells (Figures 2c and d, left panels) . To determine whether the growth suppressive effect was due to cell-cycle arrest, apoptosis or both, we performed DNA histogram analysis. We found that on knockdown of total SNF5 for 3-5 days, growth suppression was primarily due to G 1 arrest and, to a less extent, apoptosis in MCF7 and RKO cells (Figures 2c and d, right panels) . Together, we showed that SNF5a and SNF5b can functionally compensate each other and that lack of both isoforms impairs cell proliferation. Figure 3a , PARP panel). It is well established that p53 is a critical mediator of the DNA damage response and that p53 stabilization enhances apoptosis induced by DNA damage. Therefore, we wanted to examine whether increased apoptosis was due to increased p53 stabilization. Surprisingly, in contrast to an early report that loss of SNF5 in MEF cells leads to p53 stabilization, we found that the level of p53 was slightly decreased, but not increased, in RKO cells by total SNF5 knockdown, although p53 was efficiently stabilized by DNA damage (Figure 3a , p53 panel). Next, DNA histogram analysis was performed to measure the number of cells with a sub-G 1 DNA content. We showed that, on total SNF5 knockdown, DNA-damage-induced apoptosis was increased from 26.0 to 36.2% after treatment with doxorubicin, and from 6.5 to 17.7% after treatment with camptothecin ( Figure 3b ). Similar results were obtained with SNF5 knockdown MCF7 cell lines (data not shown). Furthermore, we showed that knockdown of SNF5a or SNF5b had no effect on the DNA-damage-induced apoptotic response (data not shown), which is consistent with the above results that knockdown of one isoform had little if any effect on cell proliferation (Figure 2b ). Together, these data indicate that SNF5 has a protective role in the DNA damage response.
SNF5 knockdown impairs p53-dependent transcription of p21 and MDM2
The p53 protein functions as a sequence-specific transcription factor that activates or inhibits transcription of various target genes. We sought to determine whether endogenous SNF5 is required for p53 to induce its target genes. To explore this, we examined induction of p21 and murine double minute 2 (MDM2) in MCF7 cells, in which total SNF5 or one isoform was inducibly knocked down. We found that, on treatment with doxorubicin or Nutlin-3, an inhibitor of p53-MDM2 interaction, p53 was stabilized and subsequently p21 and MDM2 were induced ( Figure 4a , compare lanes 1 and 9 with 3, 5, 7, 11 and 13, respectively). However, on knockdown of SNF5, the level of DNA damage-induced p53 was decreased in MCF7 cells ( Figure 4a , compare lanes 5 and 7 with 6 and 8, respectively), consistent with the above result ( Figure 3a) . Interestingly, Nutlin-3-mediated stabilization of p53 was increased on SNF5 knockdown ( Figure 4a , compare lanes 11 and 13 with 12 SNF5 in p53 expression and cell survival via eIF4E Y Xu et al and 14, respectively), suggesting that inhibition of p53 degradation by Mdm2 inhibitor mitigates the effect of SNF5 on p53 expression. Nevertheless, the extent of p21 and MDM2 expression was still decreased in a timedependent manner when total SNF5 was inducibly knocked down (Figure 4a ), suggesting that in addition to its effect on p53 stabilization, SNF5 is necessary for p53-dependent activation of p21 and MDM2. To rule out a potential cell type-specific effect, we examined p53 transcriptional activity on SNF5 knockdown in RKO cells (Figure 4a, . We found that p53 induction of p21 and MDM2 on DNA damage was significantly inhibited by total SNF5 knockdown ( Figure 4a , compare lanes 17 and 19 with 18 and 20, respectively). In addition, we found that p53 stabilization was slightly decreased by SNF5 knockdown (Figure 4a , compare lanes 17 and 19 with 18 and 20, respectively), consistent with the above result ( Figure 3a) . Next, we examined whether each individual SNF5 has an effect on p53-dependent transcription and showed that the expression of p53 and p21 was not consistently decreased on knockdown of either SNF5a or SNF5b, along with or without treatment of doxorubicin or camptothecin in MCF7 cells (Figure 4b ). To determine whether the impaired induction of p21 and MDM2 protein is due to decreased expression of their transcripts, we performed northern blot analysis and found that the level of p21 and MDM2 transcripts, Figure 4 SNF5 knockdown impairs p53-dependent p21 and MDM2 transcription. (a) Western blots were prepared using extracts from MCF7-SNF5-KD#73 and RKO-SNF5-KD#10 cells that were uninduced (À) or induced ( þ ) to express SNF5 siRNAs for 72 h and then treated with 0.5 mm doxorubicin, 0.25 mm camptothecin or 2.5 mm Nutlin for 0-8 h. The blots were analyzed with antibodies against p53, p21, MDM2 and actin. (b) Western blots were prepared using extracts from MCF7-SNF5a-KD#30 or MCF7-SNF5b-KD#25 cells that were uninduced (À) or induced ( þ ) to knock down SNF5a or SNF5b for 72 h and then treated with 0.5 mm doxorubicin or 0.25 mm camptothecin (CPT) for 6 h. The blots were analyzed with antibodies against p53, p21 and actin. (c) Northern blots were prepared with total RNAs isolated from MCF7-SNF5-KD#73 cells that were uninduced (À) or induced ( þ ) to express SNF5 siRNAs for 72 h, along with treatment of 0.5 mm doxorubicin or 0.25 mm camptothecin for 6 h. The blots were probed with 32 Plabeled cDNAs derived from MDM2, p21 and GAPDH genes. (d) Top panel: schematic presentation of p21 (left) and MDM2 (right) promoters with the locations of the p53 responsive elements and PCR primers used for chromatin immunoprecipitation assay. Bottom panel: knockdown of SNF5 decreases the ability of p53 to bind to the p53-responsive element in p21 (left) and MDM2 (right) promoters. MCF7-SNF5-KD#73 cells were uninduced (À) or induced ( þ ) to knock down SNF5 for 72 h followed by mock treatment or treatment with 0.5 mm of doxorubicin or 0.25 mm of camptothecin for 8 h. Chromatin immunoprecipitation assay was performed as described in Materials and methods.
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Y Xu et al although upregulated on treatment with doxorubicin or camptothecin, was markedly decreased on total SNF5 knockdown ( Figure 4c , compare lanes 3 and 5 with 4 and 6, respectively). Mdm2 transcripts were induced in MCF7 cells treated with camptothecin, which was decreased by SNF5 knockdown (longer exposure, data not shown). As a key component of the chromatin remodeling complex, SNF5 may regulate p53 transcriptional activity by altering the DNA-binding activity of p53 to its target genes, including p21 and Mdm2. To test this, we examined the binding of p53 to p21 and Mdm2 promoters by chromatin immunoprecipitation assay, with MCF7 cells uninduced or induced to knock down SNF5, along with or without treatment with doxorubicin or camptothecin for 8 h. The p53-DNA complexes were immunoprecipitated with anti-p53, as well as with mouse immunoglobulin G as a control. PCR was performed to amplify the region spanning the p53 responsive elements in the p21 and MDM2 genes with primers shown in Figure 4d (top panel). We showed that the extent of p53 binding to the p21 and MDM2 promoters was increased in MCF7 cells on treatment with doxorubicin or camptothecin ( Figure 4d , bottom panels, compare lanes 1 and 7 with lanes 3, 5, 10 and 12, respectively). No DNA fragment was enriched by control antibody (Figure 4d , immunoglobulin G panels). Interestingly, we found that SNF5 knockdown markedly inhibited p53 to bind to the p21 and MDM2 promoters (Figure 4d , bottom panels, compare lanes 3, 5, 9 and 11 with 4, 6, 10 and 12, respectively), consistent with the requirement of SNF5 for p53 induction of p21 and Mdm2 in MCF7 cells (Figures 4a and c) . Taken together, these data suggest that SNF5 is required for p53 transcriptional activity, and induction of prosurvival p53 targets, including p21 and MDM2, may have a role in SNF5 prosurvival activity.
SNF5 knockdown inhibits p53 translation but not protein stability It is well established that p53 protein stability is regulated by posttranslational modifications, leading to accumulation of p53 on DNA damage (Scoumanne and Chen, 2008) . As p53 expression was found to be decreased in cells on knockdown of SNF5, we reasoned that p53 protein stability may be regulated by SNF5. To test this, we measured p53 protein half-life and found that on inhibition of new protein synthesis with cycloheximide, p53 protein was found to be rapidly degraded in both MCF7 and RKO cells (Figures 5a and  b, lanes 1-7) . However, there was no substantial difference in the stability of p53 protein between control and SNF5 knockdown cells (Figures 5a and b , compare lanes 1-7 with 8-14, respectively). Next, we examined the rate of p53 translation, as translation is found to regulate p53 expression (Maltzman and Czyzyk, 1984; Takagi et al., 2005) . To test this, we labeled newly synthesized p53 protein with 35 S-methionine for a short period of 30 min in MCF7 cells uninduced or induced to knock down SNF5. We showed that, on knockdown of SNF5, the level of newly synthesized p53 protein was markedly decreased in MCF7 cells under both control and stress-induced conditions (Figure 5c , compare lanes 5 and 11 with 6 and 12, respectively).
SNF5 knockdown induces AMPK phosphorylation and inhibits eIF4E expression
Previous report showed that mice with liver-specific inactivation of SNF5 died of severe impaired energy metabolism, which was due to downregulation of many genes involved in gluconeogenesis, as well as glucogen storage (Gresh et al., 2005) . As an energy sensor, adenosine monophosphate-activated protein kinase (AMPK) is activated under energy stress to coordinate glucose metabolism with cell proliferation. To test this, we measured the levels of activated AMPK in SNF5-KD MCF7 and RKO cells (MCF7-SNF5-KD#73 and RKO-SNF5-KD#10) as well as in control MCF7 and RKO cells (MCF7-pcDNA6-TR#7 and RKO-pcDNA6-TR#13). We found that, on SNF5 knockdown, activated AMPK was markedly increased (Figure 6a , compare lanes 3 and 7 with 4 and 8, respectively), suggesting that AMPK has a role in the SNF5 prosurvival pathway.
To further show how SNF5 regulates cell survival, we had to identify potential SNF5 targets, which are not directly regulated by p53. Thus, we performed microarray analysis with Affymetrix GeneChip with RNAs purified from MCF7 cells uninduced or induced to knock down SNF5 for 3 days. We found that many genes were downregulated (Table 1) , including p21, S100a8 and S100a9, which were also found to be altered in mice on liver-specific inactivation of SNF5 (Gresh et al., 2005) . Among these was eIF4E, an initiation factor for protein translation. eIF4E is found to be overexpressed in many tumors and to have transforming and antiapoptotic activities (Graff et al., 2008) . Thus, western blot analysis was performed to confirm the microarray study and showed that the expression level of eIF4E along with p53 was inhibited by knockdown of SNF5 regardless of treatment with doxorubicin ( Figure 6b , compare lanes 1 and 3 with 2 and 4, respectively).
We showed that p53 translation but not stability is controlled by SNF5 (Figure 5c ). We also showed that eIF4E expression is decreased by SNF5 knockdown (Figure 6b ). As a key factor for translation, we reasoned that SNF5 regulation of p53 may be mediated through eIF4E. To test this, eIF4E was constitutively expressed in RKO cells in which endogenous SNF5 can be inducibly knocked down. We showed that, on knockdown of SNF5, the level of endogenous eIF4E was decreased, whereas exogenous myc-tagged eIF4E was constitutively expressed (Figure 6c , left panel, compare lanes 1 and 3 with 2 and 4, respectively). Interestingly, we observed that the decreased expression of p53 due to knockdown of SNF5 was abrogated, regardless of treatment with doxorubicin ( Figure 6c, left panel) . Furthermore, we found that on restoration of eIF4E, SNF5 knockdown cells regained the ability to proliferate, as measured by colony formation assay (Figure 6c , right panel). Taken together, these data suggest that eIF4E is a mediator of SNF5 in p53 expression and cell survival.
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Discussion
Through inducible knockdown of one or both SNF5 isoforms in MCF7 and RKO cells, several novel observations were made: (1) SNF5a and SNF5b are functionally redundant and compensatory in their expression, and knockdown of either one alone has no effect on cell survival; (2) knockdown of SNF5 inhibits cell survival by inducing G 1 arrest and, to a lesser extent, apoptosis; (3) SNF5 is a coactivator required for p53 transcriptional activity and (4) p53 translation was inhibited by reduced eIF4E expression and possibly enhanced activity of AMPK (Figure 6d) .
We showed that knockdown of SNF5 leads to growth inhibition and loss of survival, which is consistent with earlier reports (Isakoff et al., 2005; Klochendler-Yeivin et al., 2006) . However, the mechanisms by which lack of SNF5 inhibits cell survival are different. In MEFs with SNF5 knockout, p53 is activated and subsequently induces cell-cycle arrest and apoptosis (Isakoff et al., 2005; Klochendler-Yeivin et al., 2006) . Here, in human carcinoma cells with SNF5 knockdown, p53 expression is decreased along with decreased expression of eIF4E (Figures 6a-b) . When the decreased expression of endogenous eIF4E is compensated by exogenous eIF4E in SNF5-KD cells, p53 expression is restored (Figure 6c ). We also found that SNF5 knockdown leads to increased AMPK activation (Figure 6a) . AMPK is an inhibitor of the AKT prosurvival pathway and AMPK activation also inhibits mammalian target of rapamycin kinase and, subsequently, translation (Inoki et al., 
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Y Xu et al 2003a Xu et al , 2003b Gwinn et al., 2008) . Thus, we hypothesize that inhibition of eIF4E and activation of AMPK are the mechanisms by which SNF5 controls cell survival and p53 expression by translation. Thus, future study is needed to address how activation of AMPK and decreased expression of eIF4E coordinately mediate SNF5 in regulating p53 expression and cell survival. The defective p53 pathway caused by SNF5 knockdown is consistent with the in vivo observation that p53 knockout cooperates with SNF5 knockout to promote cancer susceptibility in mice, including early onset and high penetrance (Isakoff et al., 2005; Klochendler-Yeivin et al., 2006) . Thus, the question arises as to how a lack of SNF5 in MEF cells increases, whereas knockdown of SNF5 in human carcinoma cells decreases, p53 expression? One explanation is simply the difference between species: humans vs rodents. The other explanation is that in MEF cells, persistent lack of SNF5 generates severe stresses, potentially including DNA damage, which then activate and stabilize p53. However, in this study, SNF5 was inducibly knocked down. In addition, siRNA knockdown of SNF5 was transient and incomplete. Together, inducible and incomplete knockdown of SNF5 may not be sufficient to generate stresses, such as DNA damage, to activate p53, although SNF5 knockdown is sufficient to inhibit cell survival.
Figure 6 SNF5 knockdown inhibits p53 translation and cell survival through enhanced AMPK phosphorylation and decreased eIF4E expression. (a) SNF5 knockdown enhanced AMPK phosphorylation. Western blots were prepared using extracts from MCF7-pcDNA6-TR#7, MCF7-SNF5-KD#73, RKO-pcDNA6-TR#13 and RKO-SNF5-KD#10 that were cultured with ( þ ) or without (À) tetracycline for 72 h. The blots were analyzed with antibodies against phospho-AMPK, SNF5 and actin. (b) SNF5 knockdown inhibits eIF4E expression. Western blots were prepared using extracts from RKO-SNF5-KD#10 that were uninduced (À) or induced ( þ ) to knock down SNF5 for 72 h and then treated with 0.5 mm doxorubicin for 6 h. The blots were analyzed with antibodies against SNF5, eIF4E, p53 and actin. (c) Left panel: overexpression of myc-tagged eIF4E restores p53 expression in RKO cells in which SNF5 is inducibly knocked down. Western blots were prepared with extracts from eIF4E-producing RKO cells, which were uninduced (À) or induced ( þ ) to knock down SNF5 for 3 days and then probed with antibodies against SNF5, myc-tag, eIF4E, p53 and actin. Right panel: overexpression of myc-tagged eIF4E rescues the proliferation defect of RKO cells in which SNF5 is inducibly knocked down. 
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It is well established that SNF5 is a tumor suppressor and loss of SNF5 predisposes humans and mice to spontaneous tumor formation (Roberts and Orkin, 2004) . However, SNF5 deficiency in MEF cells and in human tumor cells leads to growth suppression, which cannot be rescued by inactivation of p53 (Isakoff et al., 2005; Klochendler-Yeivin et al., 2006) . This suggests that SNF5 is required for proper expression of prosurvival genes. Consistent with this notion, we, along with others (Gresh et al., 2005) , showed that expression of many prosurvival genes, including p53, p21 and eIF4E, was decreased on SNF5 knockdown or knockout. Conversely, to transform cells in the absence of SNF5, it is necessary that other prosurvival pathways must be activated to counter SNF5 deficiency-induced growth suppression. Indeed, expression of cyclin D1 and c-Myc was markedly increased in SNF-deficient mouse and human tumors (McKenna et al., 2008) . However, although lack of p53 promotes SNF5 deficiency-induced tumor formation (Isakoff et al., 2005; KlochendlerYeivin et al., 2006) , there is no evidence that SNF5 deficiency leads to increased p53 mutation in mouse and human tumors. In contrast, a recent study showed that loss of SNF5 does not lead to genomic instability (McKenna et al., 2008) . As genomic instability is correlated with a high frequency of p53 mutation in human cancers (Brosh and Rotter, 2009) , it is unlikely that lack of genomic instability in SNF5-deficient tumors would increase the frequency of p53 mutation. In addition, considering that knockdown of SNF5 leads to decreased expression and activity of the p53 pathway (this study) and lack of genomic instability in SNF5-knockout mice (McKenna et al., 2008) , it suggests that there is no selective pressure to mutate the p53 gene.
SNF5 functions as coactivator and co-repressor (Sif et al., 2001; Martens and Winston, 2003) , and many genes are regulated by SNF5, including approximately 6% of genes in the whole genome of yeast (Holstege et al., 1998; Sudarsanam et al., 2000) and up to 70% of genes in mouse liver (Gresh et al., 2005) . Consistent with this, the transcriptional activity of p53 was found to be enhanced by co-transfection of SNF5 (Lee et al., 2002) . Here, we found that SNF5 is required for p53 to induce expression of endogenous p21 and Mdm2. We note that in MCF7 cells treated with Nutlin-3, an inhibitor of Mdm2, p53 was accumulated but its ability to induce p21 and Mdm2 was still inhibited by SNF5 knockdown (Figure 4a ). It should also be noted that in SNF5 knockout mouse hepatic cells, p21 expression was found to be markedly inhibited (Gresh et al., 2005) , consistent with the effect of SNF5 knockdown in human carcinoma cells (this study).
Materials and methods
Plasmids
To generate inducible siRNA constructs against SNF5, we designed two individual siRNAs to target total SNF5 and one each was designed to target SNF5a or SNF5b. These siRNAs were separately cloned into pBabe-H1 vector as previously described (Xu et al., 2007) . The constructs that target total SNF5 were designated pBabe-H1-siSNF5-1049 and pBabe-H1-siSNF5-1063. The constructs that target SNF5a and SNF5b were designated pBabe-H1-siSNF5a and pBabe-H1-siSNF5b, respectively. The sense oligonucleotide in pBabe-H1-siSNF5-1049 (targeting region shown in upper case) is gatccccGGACATGTCAGAGAAGGAGAACttcaagagaGTT CTCCTTCTCTGACATGTCCtttttggaaa and the antisense oligonucleotide is agcttttccaaaaaGGACATGTCAGAGAA GGAGAACtctcttgaaGTTCTCCTTCTCTGACATGTCCggg. The sense oligonucleotide in pBabe-H1-siSNF5-1063 is gatcccc GGAGAACTCACCAGAGAAGTT ttcaagagaAACTTCTCT GGTGAGTTCTCCtttttggaaa and the antisense oligonucleotide is agcttttccaaaaa GGAGAACTCACCAGAGAAGTT tctcttgaaAACTTCTCTGGTGAGTTCTCCggg. The sense oligonucleotide in pBabe-H1-siSNF5a is gatccccAACACT AAGGATCACGGATACttcaagagaGTATCCGTGATCCTT AGTGTTtttttggaaa and the antisense oligonucleotide is agcttttccaaaaaAACACTAAGGATCACGGATACtctcttgaaGT ATCCGTGATCCTTAGTGTTggg. The sense oligonucleotide in pBabe-H1-siSNF5b is gatccccGTCACATGATCACG GATACACGttcaagagaCGTGTATCCGTGATCATGTGAC tttttggaaa and the antisense oligonucleotide is agcttttccaaaaa GTCACATGATCACGGATACACGtctcttgaaCGTGTATCC GTGATCATGTGACggg.
Cell culture and generation of stable cell lines MCF7 and RKO cells were cultured in Dulbecco's modified Eagle's medium supplement with 8% tetracycline-free fetal bovine serum and antibiotics. To generate MCF7 and RKO cell lines in which SNF5, SNF5a or SNF5b can be inducibly knocked down under the control of the tetracycline-inducible promoter, we transfected each siRNA expression vector into MCF7-pcDNA6-TR-7 and RKO-pcDNA6-TR-13 cells, both of which express a tetracycline repressor by pcDNA6 (Liu and Chen 2006) . SNF5 knockdown cell lines were selected with puromycin and confirmed by western blot analysis. To generate cell lines in which myc-tagged eIF4E is stably overexpressed and SNF5 is inducibly knocked down, we Growth rate analysis, colony formation assay and DNA histogram analysis Growth rate was measured as described (Xu et al., 2007) . Briefly, 5 Â 10 4 of MCF7 cells or 3 Â 10 4 of RKO cells were seeded with or without tetracycline in triplicate. Attached cells were counted at the indicated times. For colony formation assay, 500 MCF7 cells and 300 RKO cells seeded in six-well plates were cultured in the absence or presence of tetracycline (1.0 mg/ml) for 11-14 days. DNA histogram analysis was carried out as described (Xu et al., 2007) . Briefly, cells seeded at 2 Â 10 5 per well were cultured with or without tetracycline, along with treatment of a DNA damage agent, for various times. The percentages of cells in the sub-G 1 , G 1 , S and G 2 -M phases were determined using the CELLQuest program (BD Biosciences, San Jose, CA, USA).
Western blot analysis
Whole-cell extracts were prepared by lysing cells with 2 Â SDS sample buffer. Proteins were separated on 7-10% SDSpolyacrylamide gel electrophoresis, transferred onto a nitrocellulose membrane and probed with indicated antibodies, followed by enhanced chemiluminescence detection. Antibodies against SNF5 (BAF47), eIF4E and PARP were purchased from BD Pharmingen (San Diego, CA, USA). Phospho-AMPK-a (Thr172) antibody was purchased from Cell Signaling (Danvers, MA, USA); p21 (C19) and MDM2 (SMP14) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against p53, HA and actin were as described (Xu et al., 2007) .
Affymetrix GeneChip assay and northern blot analysis Total RNAs were isolated from MCF7-SNF5-KD#73 cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). U133 plus GeneChip was purchased from Affymetrix (Santa Clara, CA, USA), which contains oligos representing 37 000 unique human transcripts. GeneChip analysis was performed according to the manufacturer's instructions. Northern blot analysis and preparation of p21, MDM2 and glyceraldehyde-3-phosphate dehydrogenase probes were as described previously (Chen et al., 1995) .
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed as previously described (KL Harms and Chen, 2005) . After induction ( þ ) or no induction (À) of SNF5 siRNA for 72 h, cells were treated with doxorubicin or camptothecin for 8 h and cross-linked with 1% formaldehyde for 10 min at room temperature, and then sonicated to generate 500-to 1000-bp DNA fragments and were immunoprecipitated with anti-p53 (DO-1) and control mouse immunoglobulin G. After reverse cross-linking and phenol-chloroform extraction, the bound DNA fragments were purified by a Qiagen column (Qiagen, Valencia, CA, USA). PCR was performed to visualize the enriched DNA fragments. Primers designed to amplify the region from nt À2312 to À2131 in the p21 promoter were forward primer, 5 0 -CAGGCTGTGGCTCTGATTGG-3 0 , and reverse primer, 5 0 -TTCAGAGTAACAGGCTAAGG-3 0 . Primers designed to amplify the region from nt þ 3779 to þ 3969 in the MDM2 intron 1 were forward primer, 5 0 -GGATTGGG CCGGTTCAGTGG-3 0 , and reverse primer, 5 0 -GGTCTACC CTCCAATCGCCAC-3 0 .
Protein stability assay
Western blots were prepared with extracts from MCF7 and RKO cells uninduced (À) or induced ( þ ) to knock down SNF5 for 3 days along with treatment of cycloheximide (1 mg/ ml) for 0-180 min, and then probed with antibodies against p53 or actin.
Measurement of newly synthesized p53
Immunoprecipitation was performed to measure newly synthesized p53 protein in MCF7 cells, which were uninduced (À) or induced ( þ ) to knock down SNF5 for 3 days, along with or without treatment of 0.5 mm DOX for 1 h, and then labeled with [ 
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